BIO-TECHNE Corp, commonly known by its ticker symbol TECH, is a global life sciences company dedicated to empowering researchers in the pursuit of scientific advances with its high-quality reagent tools, instruments, and services. The Minneapolis-based company, established in 1976, has positioned itself as a leading player in the modern biotechnology landscape.
TECH's product portfolio offers an end-to-end solution, spanning the entire scope of the biology-based research landscape, from initial investigations to translational research and clinical diagnostic applications. It focuses on the development, manufacture, and sale of biotechnology products and diagnostic instruments, geared towards both basic research and commercial applications. The company’s product range primarily includes proteins, such as cytokines and growth factors, antibodies, commercial kits, and other reagent solutions.
The company operates globally across a multitude of scientific sectors, providing crucial tools for scientists to make impactful discoveries in critical areas of biology, including stem cell science, cancer, and cell and gene therapies. Moreover, it also supports researchers with protein analysis, gene expression, and other cellular research applications.
What essentially distinguishes BIO-TECHNE Corp is its unwavering commitment to quality, reflected in the company's careful selection of raw materials and rigorous quality control procedures, which ensures the efficacy and consistency of their products.
The company has a well-established presence in the international market and has expanded its footprint through strategic acquisitions and partnerships, which have allowed it to broaden its product portfolio and reach. The acquisitions of renowned brands like R&D Systems, Novus Biologicals, ProteinSimple, and Advanced Cell Diagnostics over the years have significantly propelled BIO-TECHNE Corp's growth trajectory and consolidated its position in the biotechnology sector.
Even in the challenging environment of the COVID-19 pandemic, BIO-TECHNE Corp managed to sustain its operations and continue its growth, mainly driven by strong demand for its COVID-19 antibodies and reagents.
As a progressive R&D driven company, it consistently invests in technological advancements and inventive solutions designed to push the boundaries of biomedical research and enable the acceleration of discovery. In terms of governance, the company operates under the leadership of a team of seasoned executives with vast industry experience, guiding TECH towards its purpose of putting engineering and precision manufacturing to work to create a healthier, better world.
In conclusion, BIO-TECHNE Corp, with its comprehensive portfolio of quality products and its dedication to fueling scientific discovery, is making a profound contribution to the biotechnology field and beyond. It is a go-to partner for researchers and a formidable contender in the life sciences industry.